The UK's Medicines and Healthcare products Regulatory Agency (MHRA) released comprehensive prescribing guidance on Saturday for Novo Nordisk's newly cleared daily oral semaglutide pill, the first GLP-1 receptor agonist in tablet form approved for weight management in Britain. The full label and clinical recommendations follow Thursday's clearance announcement, which sent Novo Nordisk's stock higher and set off immediate discussion among NHS commissioners about integration into existing obesity pathways.

The guidance outlines patient eligibility criteria, recommended starting doses, titration schedules, and contraindications, providing the clinical infrastructure that general practitioners and specialist weight-management services will need before prescribing can begin at scale. NHS England is expected to respond within days with a formal commissioning position, though budget negotiations around the pill's list price are likely to extend any broad formulary inclusion into late 2026.

Novo Nordisk confirmed that the oral formulation, taken once daily, demonstrated comparable efficacy to injectable semaglutide in pivotal trials, with patients achieving meaningful reductions in body weight over 68 weeks. Analysts at Jefferies and Morgan Stanley have noted that a pill format could dramatically expand the addressable market by reaching the substantial proportion of patients who decline injectable therapies due to needle aversion or lifestyle barriers.

The MHRA approval arrives amid a broader acceleration of obesity pharmacotherapy in the UK, where NHS waiting lists for specialist weight services remain lengthy. Patient advocacy groups, including Obesity UK, welcomed the development and called on NHS England to prioritise rapid access assessments so that the oral option reaches patients through primary care rather than exclusively through specialist clinics.

Novo Nordisk's chief medical officer for Europe indicated in a statement that the company would work closely with NICE and NHS England to support a health technology appraisal process, with a submission expected in the coming weeks. The company also acknowledged an unrelated cybersecurity incident disclosed earlier this week, stressing that no patient clinical data was compromised and that regulatory and commercial timelines remain unaffected.